Geneva, May 18 -- International Clinical Trials Registry received information related to the study (ChiCTR2600124298) titled 'Firmonertinib (160mg) as First-line Therapy for Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR/TP53 Co-Mutation: An Open-Label, Single-Arm, Multicenter Clinical Study' on May 9.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: The Second Affiliated Hospital of Nanjing Medical University
Condition:
Non-small cell lung cancer
Recruitment Status: Recruiting
Phase: 2
Date of First Enrollment: 2025-10-29
Target Sample Size: Experimental group:30;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=276407
Publishe...